Evidence map›Paper›PMID 40694284›Full record

Observational studyJapanese journal of ophthalmology2026

Six-month comparative outcomes of aflibercept and faricimab in treatment-naïve macular edema secondary to branch retinal vein occlusion.

Taiichi Hikichi, Haruka Kurabe, Amane Notoya, Yuuna Oguro, Misaki Hirano, Yumeka Doi

Abstract readObservational StudyComparative Study
PubMed Publisher
In one paragraph

Observational study in Japanese journal of ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Faricimab: current evidence for the treatment of retinal vein occlusion.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026
    Pooled it
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Taiichi HikichiHikichi Eye Clinic, Kita-7 Nishi-5 7-1 Kita-Sky-Building, 14 Floor, Kita-ku, Sapporo, 060-0807, Japan. thikichi@hikichi-eye.jp.
Haruka KurabeHikichi Eye Clinic, Kita-7 Nishi-5 7-1 Kita-Sky-Building, 14 Floor, Kita-ku, Sapporo, 060-0807, Japan.
Amane NotoyaHikichi Eye Clinic, Kita-7 Nishi-5 7-1 Kita-Sky-Building, 14 Floor, Kita-ku, Sapporo, 060-0807, Japan.
Yuuna OguroHikichi Eye Clinic, Kita-7 Nishi-5 7-1 Kita-Sky-Building, 14 Floor, Kita-ku, Sapporo, 060-0807, Japan.
Misaki HiranoHikichi Eye Clinic, Kita-7 Nishi-5 7-1 Kita-Sky-Building, 14 Floor, Kita-ku, Sapporo, 060-0807, Japan.
Yumeka DoiHikichi Eye Clinic, Kita-7 Nishi-5 7-1 Kita-Sky-Building, 14 Floor, Kita-ku, Sapporo, 060-0807, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo compare the 6-month outcomes of aflibercept and faricimab in treatment-naïve macular edema secondary to branch retinal vein occlusion (BRVOME). STUDY

designRetrospective observational study.

methodsThe charts of consecutive treatment-naïve eyes with BRVOME treated with intravitreal injection therapy between December 2023 and August 2024 at Hikichi Eye Clinic (Sapporo, Japan) were reviewed; all eyes treated between December 2023 and April 2024 were administrated with aflibercept and all eyes treated between May 2024 and August 2024 were administrated with faricimab. Best-corrected visual acuity (BCVA) and central foveal thickness (CFT) were assessed at baseline, 1, 3, and 6 months. Injection frequency and safety were also evaluated.

resultsFifty-four eyes (29 aflibercept, 25 faricimab) were included. Both groups showed significant improvement in BCVA (from 0.39 ± 0.29 to 0.09 ± 0.23) and CFT (from 617 ± 132 to 201 ± 68 µm) over 6 months (p < 0.001). The mean number of injections was significantly lower in the faricimab group (1.96 ± 0.68) than the aflibercept group (2.45 ± 0.87; p = 0.024). No serious adverse events were reported.

conclusionFaricimab achieved similar visual and anatomical outcomes to aflibercept while requiring fewer injections, suggesting a potential advantage in reducing treatment burden.

Indexed as

Macular EdemaReceptors, Vascular Endothelial Growth FactorRecombinant Fusion ProteinsRetinal Vein OcclusionVisual AcuityAgedAged, 80 and overAngiogenesis InhibitorsAntibodies, BispecificFemaleFluorescein AngiographyFollow-Up StudiesFundus OculiHumansIntravitreal InjectionsMacula LuteaafliberceptAngiogenesis InhibitorsAntibodies, BispecificfaricimabReceptors, Vascular Endothelial Growth FactorRecombinant Fusion ProteinsAfliberceptBranch retinal vein occlusionFaricimabIntravitreal injectionMacular edema

Identifiers

PMID40694284

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.